文献速递细菌感染、耐药与抗菌药物发热待查

免疫功能受损患者菌血症抗生素治疗时长:BALANCE 试验事后亚组分析

Duration of antibiotic therapy for bacteraemia in immune compromised hosts-a post-hoc subgroup analysis of the Bacteremia Antibiotic Length Actually Needed For Clinical Effectiveness (BALANCE) randomized clinical trial.
PubMed 文献 · Clin Microbiol Infect · 2026-06-09

该分析基于 BALANCE 随机临床试验的免疫功能受损亚组(1037 例,占 28.7%),比较 7 天与 14 天抗生素治疗。90 天全因死亡率在 7 天组为 20.1%,14 天组为 23.7%(风险差 -3.6%,95%CI -8.6–1.4,p=0.16),提示短疗程对该亚组可能足够。

要点

  • 免疫功能受损菌血症患者中,7 天与 14 天抗生素治疗的 90 天死亡率无显著差异。
  • 该亚组以实体恶性肿瘤(75.4%)最常见,中性粒细胞减少和移植患者被排除。
  • 结果来自事后亚组分析,临床决策仍需结合个体情况。

核心结论

  • BALANCE 试验的免疫功能受损亚组事后分析提示,7 天短疗程抗生素治疗对菌血症可能足够。

研究设计与样本

  • BALANCE 随机临床试验的事后亚组分析,聚焦免疫功能受损患者,共 1037 例(占 28.7%),530 例随机至 7 天组、507 例至 14 天组。
  • 主要结局为 90 天死亡率,主分析为意向治疗人群,敏感性分析为改良意向治疗人群中生存≥7 天者。

主要发现

  • 意向治疗人群 90 天全因死亡率:7 天组 106/528(20.1%),14 天组 120/507(23.7%),风险差 -3.6%(95%CI -8.6–1.4,p=0.16)。
  • 改良意向治疗分析 90 天死亡率:7 天组 104/526(19.8%),14 天组 117/504(23.2%),风险差 -3.4%(95%CI -8.5–1.6,p=0.18)。
  • 两臂实际抗生素使用中位数(四分位距)分别为 8(7–11)天与 14(14–15)天。

关键数值与推荐

  • 免疫功能受损类型构成:实体恶性肿瘤 75.4%、白血病/淋巴瘤 9.7%、化疗 15.4%、使用糖皮质激素 4.7%、HIV/AIDS 2.3%。
  • 尽管正式排除,仍有少量中性粒细胞减少患者入组(2.5%)。

临床怎么用

  • 对免疫功能受损的菌血症患者,可考虑 7 天抗生素疗程,但需结合感染源、病原学和临床反应个体化决策。

局限性

  • 为事后亚组分析,非预设主要分析,统计效能有限。
  • 中性粒细胞减少(<0.5×109/L)和移植患者被排除,结论不适用于这些人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The Bacteremia Antibiotic Length Actually Needed For Clinical Effectiveness (BALANCE) randomized clinical trial demonstrated 7 days to be noninferior to 14 days of antibiotics for bacteraemia. Uncertainty remains as to whether shortened treatment durations are sufficient for immune compromised patients. METHODS: BALANCE excluded patients with neutropenia (<0.5 × 109/L) and transplantation but allowed enrolment of other forms of immune compromise; this post-hoc subgroup analysis focused on these immune compromised patients. The primary outcome was 90-day mortality. The primary analysis was in the intention-to-treat population with sensitivity analyses among the modified intention-to-treat population limited to those who survived ≥7 days. RESULTS: Among BALANCE patients, 1037 (28.7%) were considered immune compromised; 530 were randomized to receive 7 days of antibiotics and 507 to receive 14 days. The most common types of immune compromise included solid malignancies (75.4%), leukaemia/lymphoma (9.7%), chemotherapy (15.4%), corticosteroid use (4.7%), and HIV/AIDS (2.3%). Despite being formally excluded, a small number of neutropenic patients were enrolled (2.5%). Patients received a median (interquartile range) of 8 (7-11 days) versus 14 (14-15 days) days of antibiotics in the two arms. All-cause 90-day mortality in the intention-to-treat population was 106/528 (20.1%) in the 7 days arm and 120/507 (23.7%) in the 14 days arm (risk difference, -3.6%; 95% CI, -8.6-1.4; p = 0.16). In the modified intention-to-treat analysis, 90-day mortality was 104/526 (19.8%) in the 7 days arm and 117/504 (23.2%) in the 14 days arm (risk difference, -3.4%; 95% CI -8.5-1.6, p = 0.18). CONCLUSIONS: This post-hoc analysis of the immune compromised subgroup of the BALANCE randomized controlled trial suggests that the shorter treatment duration was sufficient for bacteraemia in these patients.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Hamani M, Pinto R, Lee TC, et al. Duration of antibiotic therapy for bacteraemia in immune compromised hosts-a post-hoc subgroup analysis of the Bacteremia Antibiotic Length Actually Needed For Clinical Effectiveness (BALANCE) randomized clinical trial. Clin Microbiol Infect. 2026. PMID: 42264033. doi:10.1016/j.cmi.2026.06.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。